Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Calcitonin→

Calcitonin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
9007-12-9
Molecular formula
C151H226N40O45S3
Molecular weight
3417.9 g/mol
Drug class
Peptide hormonecalcitonin receptor agonist and inhibitor of osteoclastic bone resorption
Mechanism of action
Binds calcitonin receptors on osteoclasts, reducing osteoclast activity and bone resorption. It also has effects on renal calcium and phosphate handling; clinical use depends on formulation and jurisdiction.
Indications / reported uses
  • Short-term treatment of hypercalcaemia when other measures are inadequate
  • Treatment of Paget disease of bone in selected patients when alternative therapies are unsuitable
  • Selected osteoporosis indications in some jurisdictions; long-term use is restricted or discouraged in certain products because of safety concerns

Sources: US DailyMed — Calcitonin-salmon products · EMA — Calcitonin-containing medicines review · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Calcitonin Environmental Risk Assessment (ERA) (the Calcitonin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.